Research in to the induction of apoptotic cell death in glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer is another focus of the CSM. Glioblastoma cells are highly resistant to this particular form of cell death, resulting in cancer progression. In particular, the centre is interested in the role played by the Bcl-2 & IAP families in the cell death-resistant phenotype of GBM. The overall aim of the research is to increase the susceptibility of glioblastomas to apoptosis, thereby enabling current therapies to be more effective and hence improve patient survival.
GLIOTRAIN European Training Network (ETN)
Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patients dying within two years. New treatment options and effective precision medicine therapies are urgently required. The GLIOTRAIN European Training Network (ETN), which comprises 9 funded beneficiaries and 14 associated partner organisations from 8 countries, will train 15 innovative, creative and entrepreneurial PhD students.
The research objective of GLIOTRAIN is to identify novel therapeutic strategies for application in GBM, while implementing state of the art next generation sequencing, systems medicine and integrative multi-omics to unravel disease resistance mechanisms. Research activities incorporate applied systems medicine, integrative multi-omics leveraging state of the art platform technologies, and translational cancer biology implementing the latest clinically relevant models.
The consortium brings together leading European and international academics, clinicians, private sector and not-for-profit partners across GBM fields of tumour biology, multi-omics, drug development, clinical research, bioinformatics, computational modelling and systems biology. Thus, GLIOTRAIN will address currently unmet translational research and clinical needs in the GBM field by interrogating innovative therapeutic strategies and improving the mechanistic understanding of disease resistance. The GLIOTRAIN ETN addresses current needs in academia and the private sector for researchers that have been trained in an environment that spans translational research, medicine and computational biology, and that can navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.
The project is led by Prof Annette Byrne, RCSI Department of Physiology and Medical Physics & RCSI Centre for Systems Medicine. Other RCSI investigators working on the project are Prof Jochen Prehn, Dr Brona Murphy and Dr Marc Sturrock, RCSI Department of Physiology and Medical Physics. The programme is funded through the Horizon 2020 Marie Skłodowska-Curie Actions Programme. Selected candidates will be offered a highly competitive stipend (as per generous Marie Skłodowska-Curie Actions funding rules).